Edwards Lifesciences (NYSE:EW) delivered a strong beat on both the top and bottom lines for the first quarter of 2026, sending shares sharply higher in after-market trading. The company reported adjusted earnings per share of $0.78, comfortably surpassing the analyst consensus estimate of $0.749. Revenue for the quarter came in at $1.65 billion, also topping the $1.64 billion analysts had been expecting. This performance translated into a notable after-market reaction, with the stock surging approximately 4.7% following the release.
Key Segments Drive Broad-Based Strength
The first quarter results were characterized by robust growth across Edwards’ core product groups. Total company sales grew 16.7% year-over-year to $1.65 billion, with constant currency growth of 12.7%. The transcatheter aortic valve replacement (TAVR) business, which remains the company’s primary revenue driver, generated $1.2 billion in sales, up 14.4% from the prior year (11.0% on a constant currency basis). Management attributed this performance to healthy U.S. demand and even faster growth outside the U.S., supported by the exit of a competitor in Europe and stable global pricing.
The transcatheter mitral and tricuspid therapies (TMTT) segment contributed $173 million in sales, driven by the company's expanding repair and replacement portfolio. Surgical sales reached $276 million, up 10.1%, fueled by continued adoption of the RESILIA tissue platform. Gross profit margin came in at 78.0% (78.2% adjusted), while adjusted operating profit margin hit 31.4%.
Outlook Raised on Strong Momentum
Based on the better-than-anticipated first quarter, Edwards raised its full-year 2026 guidance. The company now expects constant currency sales growth of 9% to 11%, up from the previous 8% to 10% range. Total company sales are projected to be between $6.5 billion and $6.9 billion, which compares favorably to the analyst consensus estimate of approximately $6.88 billion. TAVR-specific guidance was also lifted to 7% to 9% growth from 6% to 8%.
On the earnings side, Edwards raised the midpoint of its adjusted EPS guidance to a new range of $2.95 to $3.05, compared to the earlier $2.90 to $3.05. The analyst consensus for full-year EPS stood at roughly $3.01, placing the new guidance roughly in line with expectations at the midpoint. For the second quarter of 2026, the company projects total sales of $1.66 billion to $1.74 billion, covering the consensus estimate of $1.735 billion, and adjusted EPS of $0.70 to $0.76.
Positive Clinical and Regulatory Developments
Several clinical and regulatory highlights from the quarter are worth noting. The company pointed to renewed clinical focus on proactive disease management, citing encouraging momentum from the EARLY TAVR study and the upcoming presentation of the PROGRESS trial results later this year. In the U.S., the Centers for Medicare & Medicaid Services (CMS) is reconsidering the National Coverage Determination (NCD) for TAVR, a step that could improve patient access. In Europe, updated cardiology guidelines are reshaping clinical discussions and reinforcing TAVR's role for a broader patient population.
Within TMTT, the recent FDA approval of the SAPIEN M3 system expands Edwards’ mitral portfolio, while the PASCAL repair platform continues to see increased adoption. The company also noted positive physician feedback on the EVOQUE tricuspid replacement system, supported by new clinical data presented at the American College of Cardiology (ACC) session.
Market Reaction Reflects Execution and Outlook
The after-market price jump of nearly 4.7% signals that investors are rewarding the combination of a clean earnings beat, raised guidance, and the broader narrative around expanding structural heart disease therapies. While the new full-year sales guidance brackets consensus numbers, the raised midpoint for EPS and continued momentum in both TAVR and TMTT appear to be driving the positive sentiment.
The company also disclosed that it completed a $500 million accelerated share repurchase (ASR) program during the quarter, with approximately $1.5 billion remaining under its authorized buyback program.
For more historical earnings data and future projections, visit the Edwards Lifesciences earnings page and the analyst ratings page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research or consult a financial professional before making any investment decisions.